On August 27, 2026, Morgan Stanley bought 2.77 million shares of PHARMARON (H shares) at an average of HKD 29.6166 per share, involving about HKD 81.90 million.
Prior to the acquisition, Morgan Stanley's long position in PHARMARON was 17.74 million shares, representing 4.95%; following the acquisition, the holding changed to 20.51 million shares, with the long position ratio rising to 5.69%.
Source: Hong Kong Exchanges and Clearing Limited.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments